TO THE EDITOR
We read with interest the recent article by Dispenzieri et al 1 relating to use of the radiolabeled bone-seeking agent 153 Smethylenediaminetetramethyene phosphate ( 153 Sm-EDTMP; Quadramet s ) in autologous stem cell transplantation (SCT) for multiple myeloma (MM). Their findings suggest that addition of 153 Sm-EDTMP to a melphalan-based preparative regimen is well tolerated, with no increased toxicity experienced above that expected with use of melphalan alone. This potentially allows a means of augmenting antimyeloma chemotherapy without increasing toxicity.
We have also studied use of 153 Sm-EDTMP in SCT for MM, including substituting 153 Sm-EDTMP for total body irradiation (TBI) as part of a myeloablative preparative regimen in allogeneic SCT. Inclusion criteria included patients with symptomatic or progressive MM requiring systemic therapy, including stage II and III disease at diagnosis (according to Durie-Salmon criteria 2 ), as well as patients with progressive disease after previous chemotherapy, irrespective of diagnostic stage. Patients were also required to have received at least one course of conventional chemotherapy prior to SCT. HLAidentical siblings were used as stem cell donors, with either G-CSF primed bone marrow or peripheral blood stem cells used as source of stem cells.
3 T-cell depletion or other graft manipulation was not performed.
The 153 Sm-EDTMP-based preparative regimen was administered as described previously. 4, 5 Briefly, patients received an initial tracer dose of 153 Sm-EDTMP (600 MBq) to determine the degree of skeletal uptake present. Subsequently, a dose of 153 Sm-EDTMP was calculated to deliver 35 Gy to the marrow. Due to our previous experience of 153 Sm-EDTMP in autologous SCT, in which uptake of 153 Sm-EDTMP in the appendicular skeleton was noted to be poor, supplementary external beam radiation (10 Gy) was also delivered to the limbs as a single fraction 24-48 h prior to 153 Sm-EDTMP treatment. Cytotoxic chemotherapy was administered between 9 and 13 days later, depending on the individual rate of clearance of the radiopharmaceutical. Cytotoxic chemotherapy consisted of cyclophosphamide 50 mg/kg/day for 4 consecutive days, from day À5 to À2. Cyclosporin and methotrexate (15 mg/m 2 on day þ 1, then 10 mg/m 2 on days þ 3 and þ 6) were used as standard graft-versus-host disease (GVHD) prophylaxis.
In total, nine patients received a 153 Sm-EDTMP-based allogeneic SCT, including six males. Median age was 49 years (range 43-61 years). A majority (56%) had stage 3 disease at diagnosis, and eight (89%) had received 41 treatment regimen prior to allogeneic SCT (range 1-3). Three patients (33%) had received a previous autologous SCT; six (67%) had MM refractory to their previous (pre-allograft) chemotherapy.
Median follow-up post-SCT (D0 until December 2003 or last clinic visit) was 31 months (range 10-59 months). All patients surviving 43 weeks post-SCT engrafted. Transplant-related mortality at 3 months was 11%; median overall survival (OS) was 24 months. At 2 years post-SCT, OS, progression-free (PFS) and event-free survival were 48, 19 and 17%, respectively. Grade 2-4 acute GVHD developed in two patients (22%), and extensive stage chronic GVHD in four of eight patients (50%) surviving 4100 days. Only two patients (25%) surviving 43 months actually achieved a complete response post-SCT, with a partial response noted in five (63%) and no response in one (12%).
We subsequently compared the outcome of patients transplanted with the 153 Sm-EDTMP-based preparative regimen in 33 patients with MM who underwent allogeneic SCT with 'standard' cyclophosphamide-TBI (Cy-TBI) conditioning (cyclophosphamide 60 mg/kg/day for 2 days (days -5 and -4), followed by TBI 2 Gy twice daily for 3 days from day -3 to -1) at our institution during an overlapping time period. There was no significant difference in age, sex, stage at diagnosis, time from diagnosis to SCT, proportion of patients treated with multiple prior regimens, time from last therapy to allogeneic SCT, chemosensitivity of disease to last therapy or status of disease at SCT between the two groups. Median OS was similar between the two groups (P ¼ 0.92; Figure 1 ). However, on univariate analysis, 153 Sm-EDTMP-based SCT was associated with significantly inferior complete response rate (25 vs 74%; P ¼ 0.032) and PFS (median PFS 12 vs 66 months; P ¼ 0.004; Figure 2 ) with respect to Cy-TBI conditioning. Sample size was too small for an informative multivariate analysis.
Our experience with 153 Sm-EDTMP in allogeneic SCT suggests that the radiopharmaceutical is less effective than TBI in eradicating persistent MM present at the time of transplantation. Although randomized studies with greater numbers of patients are required to define the true efficacy of 153 Sm-EDTMP in eradicating MM, based on our experience, we believe that the agent should not be used as a substitute for TBI in preparative regimens in either autologous or allogeneic SCT. As such, we find the 'augmented' approach by Dispenzieri et al 1 very promising, and await with interest the results of their phase 2 trial. Mantle cell lymphoma (MCL) and follicular lymphoma (FL) are two forms of B-cell lymphoma derived from neoplastic transformation of their normal counterparts in the mantle zone and germinal center, respectively. 1 MCL is characterized in virtually all cases by t(11;14), with dysregulation of the cell cycle by upregulation of cyclin D1 located at 11q13.
1 On the other hand, FL is characterized by t(14;18) and upregulation of BCL-2 located at 18q21, which confers resistance to apoptosis on the malignant lymphoid cells. 1 ATM (A-T mutated) gene (localized to chromosome 11q22.3) encodes a cell cycle checkpoint-specific, serine-threonine kinase. In response to double-stranded DNA breaks (DSBs), ATM phosphorylates a panel of proteins including p53, Chk1, BRCA1 and Nbs1, resulting in cell cycle arrest and DNA repair, and is thus important in maintaining the integrity of the genome. This ensures passage of an intact genome in dividing cells, and elimination of cells carrying nonrepairable DSBs.
2 Mutation of ATM leads to ataxia telangiectasia, an autosomal recessive disorder, which is characterized by neurodegeneration, immunodeficiency and increased risk of cancer including lymphomas.
In addition to the upregulation of cylin D1 associated with t(11;14) in MCL, a commonly deleted region at 11q22-q23 that encompasses the ATM locus has been identified in MCL. Subsequent mutation analysis of ATM, in 12 sporadic cases of MCL, showed a deletion of one ATM gene copy in seven, all of which harbored an inactivating point mutation in the remaining allele. In addition, biallelic ATM mutations were identified in two MCL patients without 11q deletions.
3 Using a microarray to screen lymphomas from 120 patients (including 28 MCL and 18 FL) for all possible ATM coding and splice junction mutations, ATM mutations were shown to be most frequent (12/28; 43%) in the mantle cell (MCL) subtype, but absent in FL. 4 In addition to deletion and mutation, methylation of gene promoter sites has now been identified as a frequently encountered mechanism of gene silencing in tumors. Indeed, ATM is frequently methylated in breast cancer. 5 Catalyzed by DNA methyltransferase, DNA methylation involves the addition of a methyl group to the carbon 5 position of the cytosine ring in the CpG dinucleotide, to form methylcytosine. 6 In many cancers, the CpG islands of selected genes are aberrantly methylated (hypermethylated), resulting in the repression of transcription of these genes. 6 Methylation, thus, can serve as an alternative 
